Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:ATCCode |
L01XX59
|
| gptkbp:brand |
Idhifa
|
| gptkbp:CASNumber |
1446502-11-9
|
| gptkbp:developer |
gptkb:Celgene
gptkb:Agios_Pharmaceuticals |
| gptkbp:hasMolecularFormula |
C15H14N6O
|
| gptkbp:hasSMILES |
C1=CC(=CC=C1C2=NC3=NC=NC(=C3N2)N)C(=O)N
|
| gptkbp:KEGGID |
gptkb:D10841
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
IDH2 inhibitor
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3544943
89683826 DB13879 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea differentiation syndrome elevated bilirubin |
| gptkbp:synonym |
AG-221
Idhifa |
| gptkbp:target |
isocitrate dehydrogenase 2 (IDH2)
|
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
treatment of relapsed or refractory acute myeloid leukemia
|
| gptkbp:bfsParent |
gptkb:IDH2_gene
gptkb:R140Q_(IDH2) gptkb:Isocitrate_dehydrogenase |
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
enasidenib
|